Phase 2 trial in 348 nulliparous women at term with an unripe cervix awaiting induction: tafoxiparin increased cervical ripening (Bishop score) vs placebo, most with 300 mg (mean slope 0.86 vs 0.62, p=0.006). Few serious adverse events were reported.
RCTn = 348
Ekman-Ordeberg et al. Priming of labor with tafoxiparin in nulliparous term pregnant women with unripe cervix-Proof-of-concept and dose-finding results from a randomized controlled trial